Annual report March 2024
Annual educatonal meetng held on October 5[th] ,2023
Mallinckrodt Sponsored Session 10:00 - 10:40 To improve overall survival in acute GvHD by applying ECP Dr. Melhem M. Solh, Northside Hospital, Atlanta, Georgia
Sanofi Sponsored Session 10:40 - 11:20: The dual role of ROCK2 inhibitors and ECP in treating GvHD Dr Corey Cutler, Dana-Farber Cancer Institute, Boston, Massachusetts 11:20 - 11:40
11.40 - 13.00 Nurse-led Symposium: Vascular access, Vascular Issues + Audit Ms Anne McDermott, 13:00 - 14:00 Lunch and Poster viewing
14:00 - 14:45 UKPS Business meeting
14:45 - 15:30 E-CLAD Trial: Update and progress Professor Andrew Fisher, Newcastle University 15:30 - 15:45 Afternoon coffee break 15:45 - 16:15
E-CLAD: Immunology update Mr Steven Bolton, Newcastle University 16:15 - 16:45
Investigating Extracellular Vesicles in ECP Response in Patients with GvHD Dr Rachel Crossland, Newcastle University 16:45 - 17:00 Summary & Close
Research Grants:
‘Mechanisms of action of ECP therapy for GvHD, focusing on the role of EV-derived microRNAs”, which aims to further understanding the molecular mechanisms of ECP action, including EV microRNAs, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy.’
Dr Rachel Crossland newcastle University
Statement of accounts for the UKPS for Jan31 2023 to Jan 2024 presented to Board
Charity registration number: 1178321
Jan 2023 Balance: £93,968
Educatonal events:
UKPS 2023 : £4,120 (Friends House)
Research Grant Jan 2024 : New castle Uniersity £14,691.14
Mallinckr0dt Ltd. : £20,000 ( paid in as meeting support)
Current balance Sep 2019 : £102,597.26
Dr Arun Alfred 1/3/24 Treasurer UKPS